Adalimumab
Shortage resolved
The TGA records this shortage as over. Supply reaching individual pharmacies can still take time after a shortage is resolved, so your pharmacy may not have restocked yet.
7 product records on the Australian Register of Therapeutic Goods, listed in full below. The TGA last updated this information on 14 May 2026. Not medical advice.
The TGA does not publish a reason for a shortage, so Voxsanity cannot show one. Nothing on this page is an explanation of why supply is affected — that information is not in the source and is not inferred here.
This is national information. The TGA records shortages for Australia as a whole. There is no state, territory or pharmacy-level stock information in this data, and Voxsanity cannot tell you whether a particular pharmacy has a medicine in stock. Your pharmacist can.
Products affected
AMGEVITA adalimumab (rch) 40mg/0.8mL injection solution syringe
Injection, solution · ARTG 278701
Read the TGA's own shortage record for this product
- Status
- Discontinued The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
- Supply
- Reduction in supply until supply is exhausted The supplier reports reduced stock, which will run out and not be replaced.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 24 March 2027
- Expected to be resolved
- The TGA does not publish an end date for this record (it records "Unknown"). Voxsanity does not estimate one.
- TGA last updated
- 14 May 2026
What the TGA says is being done
This product will be replaced by AMGEVITA adalimumab (rch) 40mg/0.4mL injection solution syringe (ARTG ID 484554).
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
AMGEVITA adalimumab (rch) 20mg/0.4mL injection solution syringe
Injection, solution · ARTG 278702
Read the TGA's own shortage record for this product
- Status
- Discontinued The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
- Supply
- Reduction in supply until supply is exhausted The supplier reports reduced stock, which will run out and not be replaced.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 2 January 2027
- Expected to be resolved
- The TGA does not publish an end date for this record (it records "Unknown"). Voxsanity does not estimate one.
- TGA last updated
- 14 May 2026
What the TGA says is being done
This product will be replaced by AMGEVITA adalimumab (rch) 20mg/0.2mL injection solution syringe (ARTG ID 484565).
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
AMGEVITA adalimumab (rch) 40mg/0.8mL injection solution syringe within a pen injector
Injection, solution · ARTG 273536
Read the TGA's own shortage record for this product
- Status
- Discontinued The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
- Supply
- Reduction in supply until supply is exhausted The supplier reports reduced stock, which will run out and not be replaced.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 27 October 2026
- Expected to be resolved
- The TGA does not publish an end date for this record (it records "Unknown"). Voxsanity does not estimate one.
- TGA last updated
- 14 May 2026
What the TGA says is being done
This product will be replaced by AMGEVITA adalimumab (rch) 40mg/0.4mL injection solution syringe within a pen injector (ARTG ID 484553).
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
ABRILADA adalimumab 40 mg solution for injection pre-filled pen
Injection, solution · ARTG 334497
Read the TGA's own shortage record for this product
- Status
- Shortage resolved The TGA records this shortage as over. Supply reaching individual pharmacies can still take time after a shortage is resolved, so your pharmacy may not have restocked yet.
- Supply
- Available The supplier reports stock is available, though not necessarily at every pharmacy.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 1 May 2026 The TGA's dates span 3 months.
- Resolved
- 27 July 2026
- TGA last updated
- 4 May 2026
HADLIMA adalimumab 40 mg/0.4 mL solution for injection in PushTouch auto-injector
Injection, solution · ARTG 384975
Read the TGA's own shortage record for this product
- Status
- No longer published The TGA no longer publishes a shortage report for this product, so it is not recorded as being in shortage now. The TGA removes a shortage report from its database some months after the shortage ends. Your pharmacist can tell you what is in stock.
- Supply
- Available The supplier reports stock is available, though not necessarily at every pharmacy.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 30 April 2026 The TGA's dates span 3 days.
- Resolved
- 3 May 2026
- TGA last updated
- 13 April 2026
ABRILADA adalimumab 20 mg solution for injection pre-filled syringe
Injection, solution · ARTG 334496
Read the TGA's own shortage record for this product
- Status
- Discontinued The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
- Supply
- Reduction in supply until supply is exhausted The supplier reports reduced stock, which will run out and not be replaced.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 1 February 2026
- Expected to be resolved
- The TGA does not publish an end date for this record (it records "Unknown"). Voxsanity does not estimate one.
- TGA last updated
- 23 September 2025
What the TGA says is being done
Alternative brands are available.
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
ABRILADA adalimumab 40 mg solution for injection pre-filled syringe
Injection, solution · ARTG 334498
Read the TGA's own shortage record for this product
- Status
- Discontinued The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
- Supply
- Reduction in supply until supply is exhausted The supplier reports reduced stock, which will run out and not be replaced.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 1 February 2026
- Expected to be resolved
- The TGA does not publish an end date for this record (it records "Unknown"). Voxsanity does not estimate one.
- TGA last updated
- 23 September 2025
What the TGA says is being done
Alternative brands are available.
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
Terms like ARTG, TGA and PBS are explained in the glossary.
Where this comes from
Source: Medicine Shortage Reports Database, Therapeutic Goods Administration (TGA), © Commonwealth of Australia, reproduced with permission. The TGA does not endorse Voxsanity, and nothing here is presented as a TGA view. Shortage information is free for everyone on this site, with no account and no subscription.
Every product listed above links to the TGA's own shortage record for that product. The TGA's register is organised by product rather than by medicine, so there is no single TGA page covering Adalimumab as a whole; to see them together, open the TGA Medicine Shortage Reports Database and type Adalimumab into its filter box. General information about medicine shortages is on the TGA's medicine shortages page.
Voxsanity last read the register on 16 October 2026.
Not medical advice. Voxsanity republishes public government health data in plain English. Speak to your pharmacist or doctor about your own medicines. Do not stop or change how you take a medicine because of anything on this page.